Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome

Noritomo Kurosu, Hidekazu Sugiura, Chihiro Iwasaki, Yukari Asamiya, Chiari Kojima, Takahito Moriyama, Mitsuyo Itabashi, Misao Tsukada, Takashi Takei, Tetsuya Ogawa, Takumi Yoshida, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

We present the case of a 23-year-old man with steroid-resistant nephrotic syndrome due to minimal change disease who was treated with rituximab. The patient was resistant to conventional therapy. We therefore treated him with a single dose of rituximab (375 mg/m2). One month after the administration of rituximab, complete remission was achieved. However, six months later, the patient was administered a second dose of rituximab as the peripheral B cell counts began to recover. Thereafter, at present, that is, one year after the first rituximab administration, complete remission has been maintained. We conclude that rituximab may be an effective treatment agent for resistant nephrotic syndrome and the peripheral B cell count may be a useful marker in such patients for preventing disease relapse.

Original languageEnglish (US)
Pages (from-to)1901-1904
Number of pages4
JournalInternal Medicine
Volume48
Issue number21
DOIs
StatePublished - 2009

Keywords

  • Minimal change nephritic syndrome
  • Peripheral B-cell
  • Rituximab
  • Steroid-resistant nephritic syndrome

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome'. Together they form a unique fingerprint.

Cite this